Lung Transplant Rejection – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Lung Transplant Rejection – Pipeline Review, H1 2020’, provides an overview of the Lung Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lung Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Lung Transplant Rejection

– The report reviews pipeline therapeutics for Lung Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Lung Transplant Rejection therapeutics and enlists all their major and minor projects

– The report assesses Lung Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Lung Transplant Rejection

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Lung Transplant Rejection

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Lung Transplant Rejection pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

Apeptico Forschung und Entwicklung GmbH

Astellas Pharma Inc

Exscien Corp

Kamada Ltd

MimeTech Srl

Proteo Inc

Quark Pharmaceuticals Inc

Radikal Therapeutics Inc

Sangamo Therapeutics Inc

TFF Pharmaceuticals Inc

Theravance Biopharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Lung Transplant Rejection - Overview

Lung Transplant Rejection - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Lung Transplant Rejection - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lung Transplant Rejection - Companies Involved in Therapeutics Development

Amgen Inc

Apeptico Forschung und Entwicklung GmbH

Astellas Pharma Inc

Exscien Corp

Kamada Ltd

MimeTech Srl

Proteo Inc

Quark Pharmaceuticals Inc

Radikal Therapeutics Inc

Sangamo Therapeutics Inc

TFF Pharmaceuticals Inc

Theravance Biopharma Inc

Lung Transplant Rejection - Drug Profiles

alpha-1 proteinase inhibitor (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carfilzomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Exscien-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPLI-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-554 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solnatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tacrolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tacrolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-0903 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tiprelestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TX-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

udonitrectag - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lung Transplant Rejection - Dormant Projects

Lung Transplant Rejection - Product Development Milestones

Featured News & Press Releases

Oct 18, 2019: New insights into Alpha-1 Deficiency: A special scientific meeting organized by Kamada during the recent ERS congress

Feb 06, 2019: Kamada announces additional interim results from phase 2 proof of concept clinical trial of intravenous Alpha-1 Antitrypsin treatment for prevention of Lung Transplant Rejection

Jan 08, 2018: Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection

Jun 19, 2017: TxCell Appoints Lentigen Technology To Manufacture the Lentiviral Vector for Its First CAR-Treg Program in Transplant Rejection

Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection

Dec 09, 2015: Quark announces issue of U.S. patent for novel treatment of lung transplantation associated injury

Oct 05, 2015: APEPTICO receives Orphan Drug Designation by European Medicines Agency

Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection

Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs

Mar 03, 2015: APEPTICO provides update on phase IIa study of AP301 product candidate

Jul 08, 2013: APEPTICO receives research grant from Austrian Research Promotion Agency (FFG)

Apr 17, 2013: APEPTICO initiates phase II clinical trial with AP301 in patients with primary graft dysfunction following lung transplantation

Jan 31, 2013: APEPTICO announces publication of article in the journal Pulmonary Pharmacology and Therapeutics

Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program

Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Lung Transplant Rejection, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Lung Transplant Rejection – Pipeline by Amgen Inc, H1 2020

Lung Transplant Rejection – Pipeline by Apeptico Forschung und Entwicklung GmbH, H1 2020

Lung Transplant Rejection – Pipeline by Astellas Pharma Inc, H1 2020

Lung Transplant Rejection – Pipeline by Exscien Corp, H1 2020

Lung Transplant Rejection – Pipeline by Kamada Ltd, H1 2020

Lung Transplant Rejection – Pipeline by MimeTech Srl, H1 2020

Lung Transplant Rejection – Pipeline by Proteo Inc, H1 2020

Lung Transplant Rejection – Pipeline by Quark Pharmaceuticals Inc, H1 2020

Lung Transplant Rejection – Pipeline by Radikal Therapeutics Inc, H1 2020

Lung Transplant Rejection – Pipeline by Sangamo Therapeutics Inc, H1 2020

Lung Transplant Rejection – Pipeline by TFF Pharmaceuticals Inc, H1 2020

Lung Transplant Rejection – Pipeline by Theravance Biopharma Inc, H1 2020

Lung Transplant Rejection – Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development for Lung Transplant Rejection, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports